Phase 2a Study of MVA-BN-RSV Vaccination and RSV Challenge in Healthy Adults

Summary

A Phase 2a, Randomised, Double-Blinded, Placebo-Controlled Study to Assess the Safety, Immunogenicity and Efficacy of the Recombinant MVA-BN®-RSV Vaccine against Respiratory Syncytial Virus Infection in the Virus Challenge Model in Healthy Adult Participants

Timeline

Start

2021-02-22

Primary completion

2021-06-17

Completion

2021-11-02

Publications

• Jordan E, Kabir G, Schultz S, Silbernagl G, Schmidt D, Jenkins VA, Weidenthaler H, Stroukova D, Martin BK, De Moerlooze L. Reduced Respiratory Syncytial Virus Load, Symptoms, and Infections: A Human Challenge Trial of MVA-BN-RSV Vaccine. J Infect Dis. 2023 Oct 18;228(8):999-1011. doi: 10.1093/infdis/jiad108.

Drugs

Indications